Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report)'s share price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.91 and traded as low as $0.61. Seres Therapeutics shares last traded at $0.62, with a volume of 3,849,237 shares trading hands.
Wall Street Analyst Weigh In
A number of research firms have issued reports on MCRB. Chardan Capital cut their target price on shares of Seres Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, March 6th. Oppenheimer cut their price target on shares of Seres Therapeutics from $9.00 to $5.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 6th.
Read Our Latest Stock Analysis on MCRB
Seres Therapeutics Stock Performance
The firm has a market capitalization of $96.06 million, a price-to-earnings ratio of -0.71 and a beta of 2.24. The business's 50-day moving average is $0.90 and its two-hundred day moving average is $1.15.
Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.08. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.50 million. Analysts forecast that Seres Therapeutics, Inc. will post -1.15 EPS for the current year.
Institutional Trading of Seres Therapeutics
A number of large investors have recently bought and sold shares of MCRB. Commonwealth Equity Services LLC bought a new stake in Seres Therapeutics during the 3rd quarter worth approximately $26,000. Simplicity Solutions LLC bought a new stake in Seres Therapeutics during the 3rd quarter worth approximately $27,000. Stifel Financial Corp bought a new stake in Seres Therapeutics during the 4th quarter worth approximately $28,000. Wexford Capital LP bought a new stake in Seres Therapeutics during the 4th quarter worth approximately $29,000. Finally, GTS Securities LLC bought a new position in shares of Seres Therapeutics during the 3rd quarter worth approximately $32,000. 59.34% of the stock is owned by institutional investors.
About Seres Therapeutics
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
Featured Articles
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
